Comparative Pharmacology
Head-to-head clinical analysis: ADMELOG SOLOSTAR versus INSULIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADMELOG SOLOSTAR versus INSULIN.
ADMELOG SOLOSTAR vs Insulin
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lispro, a rapid-acting insulin analog, lowers blood glucose by binding to and activating the insulin receptor, leading to increased glucose uptake in peripheral tissues (e.g., skeletal muscle, fat) and suppression of hepatic glucose production.
Insulin lowers blood glucose by binding to insulin receptors on target cells, activating tyrosine kinase activity, promoting glucose uptake via GLUT4 translocation, stimulating glycogen synthesis, and inhibiting gluconeogenesis and lipolysis.
Subcutaneous injection starting dose 0.2-0.4 units/kg/day divided into 1-2 injections, or 0.1-0.2 units/kg/meal for prandial coverage; typical total daily dose 0.5-1.0 units/kg.
Individualized based on weight, insulin sensitivity, and metabolic needs. Type 1 diabetes: total daily dose (TDD) 0.3–1.5 units/kg/day, typically 50% basal (long-acting) and 50% prandial (rapid/short-acting). Type 2 diabetes: starting dose 0.1–0.2 units/kg/day or 10 units basal once daily, titrated based on fasting glucose. Intensive regimens use basal-bolus approach.
None Documented
None Documented
Terminal elimination half-life: 5-6 hours for insulin lispro; clinical context: reflects duration of glucose-lowering effect, allowing dosing before meals.
Terminal elimination half-life: 5-6 minutes for regular insulin; biphasic with initial rapid phase (4-5 min) and slower phase. Clinical context: short half-life necessitates continuous infusion or multiple daily injections.
Renal: 30-80% of dose excreted unchanged in urine; biliary/fecal: negligible.
Renal: ~60-80% (degraded in kidney); hepatic: ~20-40% (degraded in liver); only a small fraction (<1%) excreted unchanged in urine.
Category C
Category A/B
Insulin
Insulin